The improvement of doping control is an ongoing race. Techniques to fight doping are usually based on the direct detection of drugs or their metabolites by analytical methods such as chromatography hyphenated to mass spectrometry after ad hoc sample preparation. Nowadays, omic methods constitute an attractive development and advances have been achieved particularly by application of molecular biology tools for detection of anabolic androgenic steroids (AAS), erythropoiesis-stimulating agent (ESA), or to control human growth hormone misuses. These interesting results across different animal species have suggested that modification of gene expression offers promising new methods of improving the window of detection of banned substances by targeting their effects on blood cell gene expression. In this context, the present study describes the possibility of using a modified version of the dedicated Human IVD (in vitro Diagnostics) PAXgene® Blood RNA Kit for horse gene expression analysis in blood collected on PAXgene® tubes applied to the horse biological passport. The commercial kit was only approved for human blood samples and has required an optimization of specific technical requirements for equine blood samples. Improvements and recommendations were achieved for sample collection, storage and RNA extraction procedure. Following these developments, RNA yield and quality were demonstrated to be suitable for downstream gene expression analysis by qPCR techniques.
Introduction
Quantitative real-time polymerase chain reaction (qPCR) is a technique used to detect and quantify a specific sequence of DNA. [1] The DNA strands include genes that code for specific proteins involved in functional biochemical pathways, or in tissue and cell structure. To produce proteins, the DNA coding sequence (gene) is transcribed to form messenger RNA (mRNA) which, after appropriate modifications, is transported to the cytoplasm where it is translated into protein by the ribosome. In general, the number of mRNA copies (mRNA level) transcribed from a gene roughly correlates with the amount of coded protein synthesized. Therefore, the quantification of all mRNA allows the estimation of the gene expression profile, known as the 'transcriptome'. [2] When a specific transcriptomic signature is observed in a given condition, the complex profiles can serve as transcriptional 'fingerprints'. [2] Transcriptional fingerprints have been used to determine the target of drugs. [3] Pharmacological agents interact with specific cellular components (i.e., proteins) and are able to modulate either directly or indirectly the gene expression of the drug-treated cell. Thus, the transcriptome of the exposed cells can be different from those which have never been exposed to the drug. This is the basic concept of biological markers (biomarkers) which have been used for diagnostic testing for more than 50 years. This use has accelerated in the twenty-first century, especially in the field of transcriptional biomarkers. [4] Recent advances in the doping control field have been achieved by the application of molecular biology tools. In humans, gene expression profiling has been studied to control testosterone misuse, [5] RNA interference for performance enhancement, [6] microRNA as long-term biomarkers for detection of erythropoiesis-stimulating agent (ESA) [7] or to control human growth hormone [8] and recombinant human erythropoietin (EPO) [9] misuse. In addition, strategies have been described to detect possible EPO gene doping in human blood. [10] Moreover, successful results have been obtained in bovines to combat the illegal use of growth promoter. [11] [12] [13] For horses, a strategy based on blood cell mRNA expression measurement has been developed from Eprex® administered animals for doping. [14, 15] Other studies have examined the effect of exercise on muscle and blood cell transcriptomes. [16] Finally, a transcriptomic approach was also successfully carried out on horse muscle to reveal energetic pathway modifications due to pathology. [17] These interesting results across different animal species suggested that modification of gene expression offers promising new methods to improve the window of detection of banned substances by targeting their effects on blood cell gene expression. Blood is a desirable sample for doping control because it is highly accessible and can be collected using relatively simple methods from a large number of humans/animals. Moreover, blood circulates throughout the entire body and therefore potentially contains widespread biological information.
In this study, a new generic total RNA sample preparation from horse blood collected on PAXgene® tubes is described based on modifications to the human procedure. According to the manufacturer, the PAXgene® RNA tube is intended for collection, storage/stabilization, and transport of human blood RNA. Indeed, the main challenge of quantitative gene expression studies is to extract sufficient usable mRNA, to avoid degradation and permit quantification of suitable numbers of transcript. [18] [19] [20] [21] By using such stabilization systems, the RNA does not need to be extracted or stored immediately at À80°C, which was the case previously. [20] This powerful capacity of the PAXgene® tube to delay sample degradation was used in the development and applied to the horse biological passport to monitor gene expression. It should be noticed that isolating intact RNA is one of the most difficult procedures carried out in molecular biology laboratories, requiring meticulous technical skills in order to prevent degradation by ubiquitous RNases. [22] As much as possible, this work was based on the MIQE guidelines: Minimum Information for publication of Quantitative Real-Time PCR Experiments. [23] [24] [25] 
Materials and methods

Chemicals and biochemicals
Resuspension buffer (BR1), binding buffer containing guanidine thiocyanate (BR2), wash buffer 1 (BR3), wash buffer 2 (BR4), RNase-free water, proteinase K from Tritirachium album, PAXgene® RNA spin columns, PAXgene® shredder spin columns, secondary BD Hemogard® closures were included in a blood RNA kit from PreaAnalytix (Hombrechtikon, Switzerland). 384-well PCR plates, microseal adhesives, Experion RNA standard sensitivity analysis kits, RNA ladder, Experion electrode cleaner, DEPC-treated water, Iscript cDNA synthesis kits, and IQ SYBR Green supermixes were from BioRad (Marnes la Coquette, France). Tris-EDTA (TE) buffer solution pH 8 and ethanol BioUltra 99.8%, both molecular biology grade, were from Sigma-Aldrich (St Louis, MO, USA). Custom oligos were from Sigma-Aldrich (St Louis, MO, USA) and sequences were as follows: reference gene (actin-β, ENSECAT00000016856) forward primer 5 0 CCGCGAGAAGATGACCCA 3 0 , reverse primer 5 0 GCGGCC AGAGGCGTACA 3 0 and target gene (LCK, ENSECAT00000025147) forward primer 5 0 GGCCAACCTCATGAAGCA 3 0 , reverse primer 5 0 GTGACCACCGCGTAGAGC 3 0 . DNase I (RNase-free) was from Ambion (Carlsbad, CA, USA). Regenerated cellulose 100 kDa MWCO filters were from Merck Millipore Ltd (Tullagreen, Carrigtwohill, Co. Cork, Ireland). Qualitative filter paper with 2 μm particle retention was from VWR (Leuven, Belgique).
Sample collection procedure
PAXgene® blood RNA tubes were used by the veterinarians according the manufacturer's guidelines. Briefly, blood was collected by venipuncture at the jugular vein and tubes were then mixed gently by inverting them 8 to 10 times, stored upright for about 1 h at room temperature and then subjected to further processing (storage, sending, or analysis).
To optimize the RNA extraction procedure, 8 blood samples were collected in PAXgene® blood RNA tubes filled to maximum volume (2.5 mL) by a single veterinarian in our experimental facilities (Coye la Forêt, France). After sampling, tubes were handled as described and then stored at À20°C until analysis.
Regarding routine sampling conditions and to appraise the best sample collection procedure which allows for the highest RNA extraction yield, two comparisons were performed on different French trotters at training for maximum variability. After identifying the horse by its individual microchip, the PAXgene® tubes were filled with blood as previously described and according to the following procedures. (1) Comparison of the level of blood in the PAXgene® tubes: One tube was filled to maximum level (2.5 mL) with blood from a 6-year-old healthy stallion and a second tube was filled to the half of the total tube capacity with blood from a 4-year-old healthy stallion. Tubes were immediately sent to the laboratory without freeze packs after mixing and incubation for 1 h at room temperature. (2) Comparison of the effect of the storage temperatures after sampling and before sending: one tube was filled with blood from an 8-year-old gelding and stored over a weekend at temperature above +18°C and a second tube was filled with blood from a 6-year-old mare and stored over a weekend at +4°C. Both tubes were filled at maximum level and sent to the laboratory without freeze packs after the defined storage conditions.
Effect of long-term storage on total RNA recovery
According to the manufacturer's guidelines, human blood specimens can be stored for a minimum of 50 months at À20°C. A study was performed on 62 samples collected on 62 different French trotters at training over a 3-year sampling period. Samples were composed of 2 PAXgene® tubes (A and B). Samples A were processed immediately after receiving the tubes at the laboratory while samples B were stored at À20°C for 6 to 29 months before extraction. The samples B storing periods were as follows: 6 months (n = 12), 8 months (n = 4), 13 months (n = 11), 18 months (n = 3), 19 months (n = 6), 22 months (n = 5), 27 months (n = 6), 28 months (n = 4), and 29 months (n = 11). RNA yields were compared between A and B tubes from the same paired sample, which were collected from the same animal during the same venipuncture, and expressed as relative percentages of B versus A. For each long-term storage (6 to 29 months), the mean of all percentages for a defined period was calculated.
Total RNA sample preparation
This part describes the modifications of the human IVD (in vitro diagnostic) RNA purification kit optimized for horses.
Cells preparation
To develop a reproducible procedure for total RNA extractions, all PAXgene® tubes were stored for at least 24 h at À20°C before use. Prior to RNA extraction, the tubes were stored overnight in darkness at room temperature. Then, the tubes were centrifuged (20 min, 3000 g, centrifuge model 5804, Eppendorf). The supernatant was carefully discarded by pouring off the tube. After drying, the pellet containing the cells was washed with 4 mL of RNase free water. The original Hemogard® closure was removed and replaced with a clean one from the kit. The tubes were centrifuged again for 20 min at 3000 g. The supernatant was discarded and the pellet dried as described previously before RNA sample preparation applied to gene expression profiling for the horse biological passport wileyonlinelibrary.com/journal/dta adding 350 μL of modified BR1 (Table 1) ; followed by a transfer into a 2 mL processing tube.
QIAcube reagents modifications
Proteinase K, new DNAse I incubation mix and TE pH 8 elution buffer instead of BR5 (Table 1) were placed in the QIAcube tube slots (Qiagen, Courtaboeuf, France) according to the number of samples to be analyzed (between 2 and 12). The QIAcube performs the processing of the samples from raw material (blood cells pellet) up to the elution of total RNA in TE elution buffer pH 8 by means of the PAXgene® blood RNA part A program. Briefly, the proteinase K and BR2 binding buffer containing guanidine thiocyanate were mixed with the resuspended pellet and incubated for 10 min at 55°C using the included shaker-incubator. 
RNA quality/quantity
The quality of total RNA extracted from horse blood cells was checked by microcapillary electrophoresis analysis using an Experion (BioRad, Marnes la Coquette, France) and the quantity was measured using a spectrophotometer NanoDrop ND-1000 (Thermo Scientific, Les Ulis, France) according to the manufacturer's procedure.
cDNA synthesis
Each processed sample was normalized to 40 ng/μL of total RNA. The first strand cDNA was synthesized by mixing 1.2 μg of RNA with 2 μL of Iscript reverse transcriptase and 8 μL of 5× iScript reaction mix from the Iscript cDNA synthesis kit. The reaction was performed in MJ Mini thermocycler in 3 steps: priming (5 min, 25°C), elongation (30 min, 42°C) and reverse transcriptase inactivation (5 min, 85°C). The cDNA sample was stored at À80°C before quantitative PCR analysis.
Quantitative PCR (qPCR) analysis
Quantitative PCR was performed on both cDNA samples and total RNA samples. To assess the quality of total RNA extraction, qPCR was carried out on DNAse I digested and non-digested RNA. Each processed sample was normalized to 40 ng/μL of total RNA. For the amplification specificity and efficiency, cDNA from different samples was first pooled and then subjected to a tenfold serial dilution. qPCR reactions were performed with IQ SYBR Green supermix assisted by a Freedom EVO 75 (Tecan, Lyon, France) to dispense the mix and samples in 384-well plates, and were amplified and quantified in CFX 384 real-time PCR detection system (BioRad, Marnes la Coquette, France) under the following conditions. The reactions were performed in a final volume of 20 μL with primers concentration at 400 nM and either 20 ng of RNA starting quantity (RT minus control, NRT), different amounts of cDNA (20 ng to 2 pg) according to the serial dilutions, DEPC water (no template control, NTC). The cycling conditions of 40 cycles consisted of denaturation at 95°C for 10 s, annealing at 58°C for 30 s and extension at 72°C for 15 s after a 3-min hot start at 95°C. Discrimination of specific products from non-specific products and primer dimers was carried out by a melt curve obtained by gradual increase in temperature from 65 to 95°C at a rate of 0.25°C/s. Primers were designed with Beacon Designer 7 according to the recommended parameters for SYBR-Green qPCR assays: amplicon size at about 100 bp, melting temperature at 60 ± 2°C and no hairpin structure and/or primer dimers formation. Primer specificity was controlled in silico with online BLAST analysis on the Ensembl Horse genome assembly 2. [26] The qPCR results were analyzed with the CFX Manager software version 2.0.
Results and discussion
Total RNA purification from horse whole blood cells
The PAXgene® blood RNA system consists of a blood collection tube (PAXgene® tube) and an intracellular RNA purification kit dedicated to human whole blood. The first assays on horse blood samples were carried out using the generic protocol recommended by the manufacturer. Unfortunately, RNA yields and quality obtained in these conditions did not allow enough material to work for a wide set of samples and target genes. Therefore, the automated QIAcube extraction was modified. The BR1 buffer available in the kit, containing a high level of salts, was four times diluted in DEPC-treated water. The DNase I from the kit was substituted with Ambion DNase I and finally the BR5 buffer was replaced by TE pH 8 buffer. As observed, but also reported by the manufacturer, BR5 has high absorbance at 220 nm leading to high background absorbance levels. The consequence for our RNA samples was interference in the microcapillary electrophoresis analysis as well as in UV spectrophotometry analysis. The modifications are listed in Table 1 .
After RNA extraction and prior to gene expression analysis, RNA quality and integrity were checked by micro-electrophoresis on the Experion system (BioRad, Marnes la Coquette, France). Although modification of DNase I during the sample preparation had been performed, an important gDNA contamination remained in the analyzed samples. Consequently, it was decided to add a second DNase I step in the total RNA extract followed by filtration on a 100 kDa MWCO filter. Figure 1 represents the spectra recorded on the Experion system just after elution of total RNA extracted with the modified QIAcube protocol, with (blue) or without (red) an additional step of DNAse I digestion followed with a purification on 100 kDa MWCO filter. The first peak of the electropherograms corresponds to the 'lower' marker included in the kit. It was used for alignment of the sample migration and allowed comparison between analyses. For both conditions, the low molecular weight markers were equal in intensity and proved the repeatability of the micro-electrophoresis sample preparation and migration. Moreover, the electropherograms overlapped nearly perfectly and more particularly on the 18S and 28S ribosomal RNA (rRNA) peaks both in width and in height. These observations, taken together with the RNA quality indicator (RQI) values (10 for both) and 28S:18S ratios (1.95 and 2.08), demonstrated a flawless integrity in the extracted RNA. The 28S:18S rRNA ratio is frequently used to assess the quality of total RNA purified from any given sample. As 28S rRNA is around twice the quantity of 18S rRNA in intact extracted RNA, the expected total RNA ratio should be 2:1. If the rRNA are partially degraded, then it is assumed that the mRNA are also at least partially degraded leading to poor gene expression measurement capacity. [27] RQI allows the evaluation of total RNA integrity on analyses performed on the Experion microchip electrophoresis system. Briefly, the algorithm compares three regions of the electrophoretic profile: 28S region, 18S region and pre-18S regions. The highest score is 10. [28] [29] [30] Despite the DNAse I digestion integrated in the QIAcube extraction program, gDNA contamination occurred. The gDNA was clearly visible on the red curve at the end of the electrophoresis as a large peak between 55 s and 60 s. However, the additional step of both DNAse I digestion and filtration on a 100 kDa MWCO filter removed the contamination with high efficiency.
Following these results, further investigation of RNA quality assessment and particularly gDNA contamination were carried out. Thus, total RNA from 8 different samples collected from 8 different horses was extracted as previously described and then pooled together after the final elution step. After additional DNAse I digestion, quantitative PCR was performed directly on total RNA without cDNA synthesis. These reactions illustrate the amplification of gDNA contamination if present and are commonly known as RT minus controls or NRT. The amplification curves obtained for the qPCR reactions performed on total RNA are shown in Figure 2 . For both the reference and the target genes Cq values were around 30 without the additional DNAse I digestion step while they were after 40 cycles with the additional DNAse I digestion. In parallel, NTC reactions showed no amplification signal (data not shown). It can be concluded that the additional DNase I digestion improved the specific amplification of cDNA.
Our results demonstrated that after extraction, an additional DNase I digestion step combined with a purification on a 100 kDa MWCO filter was required to perform gene expression assays by qPCR without interference from gDNA contamination. Alternatively, this issue could also be addressed by designing primers to target the exon-exon boundaries. If one of the two primers was designed at the junction of two exons, no amplification Figure 1 . Electropherograms of total RNA obtained from horse whole blood cells after modified QIAcube extraction and without (red curve) or with (blue curve) an additional step of DNAse I digestion followed by purification on 100 kDa MWCO filter. Samples (n = 8) were extracted with the QIAcube, pooled and then divided into two aliquots. Prior to filtration one aliquot was subjected to DNase I digestion while the other was left untreated. Total RNA integrity was checked with the Experion System. of gDNA would be possible, even in the case of low gDNA contamination. [31] qPCR quality Several quality assessments were made of the qPCR to determine the specificity and the efficiency of the amplification. Ten-fold serial-dilutions of pooled cDNAs constituting standard curves were performed and subjected to qPCR amplification followed by melt curve. According to the reverse transcription conditions and the subsequent dilutions, the cDNA standard curve concentration range was evaluated between 20 ng to 2 pg. The standard curves and melting curves for the reference gene and the target gene are presented in Figure 3 . As previously described and as expected, no amplification signal was observed in NTC reactions indicating that primers did not anneal together and did not form primer dimers. This result also highlighted that no contamination occurred during qPCR preparation. The melt curves performed at the end of Figure 2 . gDNA contamination assessment by qPCR amplification of a reference gene (actin-β) (a) and a target gene (LCK) (b) in the RT minus controls (NRT) prepared from total RNA extracted and then purified with or without additional DNAse I digestion. Samples (n = 8) were extracted with the QIAcube, pooled and then divided into two aliquots. One aliquot was subjected to DNAse I digestion and the other not before filtration followed by qPCR amplification. All qPCR reactions were performed in duplicates. Figure 3 . Efficiency and specificity assessments of qPCR amplification for a reference gene (actin-β) and a target gene (LCK). Efficiency is determined by standard curves carried out on ten-fold serially diluted pooled cDNA and specificity by melt curves. Aliquots of cDNA were pooled and then diluted 1/10, 1/100, 1/1000, 1/10000 and 1/100000. All qPCR reactions were performed in duplicates.
the PCR program showed the fluorescence signal evolution according to the increase of temperature. As a result, when temperature reaches the melting temperature (TM) of the amplicon, double strand DNA denaturates. SYBR Green is then released and fluorescence signal collapses. The first derivate of the signal is shown in Figure 3 where the fluorescence decrease is translated as a peak at the amplicon's TM. When the amplification is specific, only one unique peak should be observed. Figure 3 highlights that for the reference gene, a unique TM was observed at 84.5°C and for the target gene, a unique TM was observed at 84°C. The amplification was thus considered as specific for the two genes. In parallel, standard curves analysis allowed us to assume that for both genes, detection limit was higher than 2 pg and lower than 20 pg of cDNA starting material. Five levels were prepared for standard curves with a highest starting quantity of 20 ng and a lowest at 2 pg. The signal amplification was observed until the 20 pg level included but not at 2 pg level. Furthermore, the ten-fold serial dilutions enabled the assessment of amplification efficiency. This parameter was extrapolated from the slope of the standard curve. In theory, for 100% amplification efficiency (i.e., material doubled at each PCR cycle), the slope should be equal to À3.3 (i.e., each ten-fold serial dilution level is separated by 3.3 Cq). [32] In our work, coefficients of regression (r 2 ) for both genes (0.999 and 0.995) validate repeatability between the replicated reactions and precision on the serial dilutions. Moreover, the slopes were equal to À3.39 and À3.29 for the reference gene and the target gene respectively which correspond to amplification efficiencies of 97.3% and 101.4% and were considered as respectable results.
Sample collection for biological passports
For the horse biological passport sample collection, a customized sample kit containing PAXgene® tubes is used by the veterinarian (Figure 4 ). Before use, the sealed horse kit is opened in presence of the trainer or equivalent. Following sample collection, blood and urine samples are split in two parts (A and B). Part A is composed of four lithium heparinized tubes, one PAXgene® RNA tube and one bottle containing urine. Part B is composed of two lithium heparin tubes, the second bottle of urine and the second PAXgene® RNA tube. The EDTA tube is sent to a different laboratory for the determination of haematological parameters. All tubes and bottles are sealed in the presence of the trainer or their representative.
During method development, the sample preparation was carried out on horse blood collected on PAXgene® tubes by a single veterinarian from LCH (Laboratoire des Courses Hippiques) experimental centre. These conditions were defined to be not consistent with routine practice associated to variability in terms of collection, transportation, tube filling or tubes in contact with bottles containing urine freshly collected (temperature around 38°C). Therefore, to appraise the best 'routine' conditions for sample collection and storage before sending, a blind test was performed with samples collected in different conditions described in the Sample collection procedure section of the Material and Methods. After extraction, total RNA was separated with the Experion RNA Std Sens analysis Kit and results are presented in Figure 5 . The 28S and 18S rRNA peaks are indicated on the four profiles. Figure 5a presents the worst electropherogram with a large quantity of RNA degradation and a low 28S:18S ratio near to 1 and a RQI value equal to 6.7. This result corresponds to the sample stored 2 days at room temperature and filled with a maximum volume of blood. Figure 5b describes the second lowest 28S:18S ratio but with an acceptable RQI (7.9) corresponding to the sample filled with a low volume of blood and sent immediately. Figures 5c and 5d present better results with 28S:18S ratios near to 2:1 with a high RQI due to the low level of RNA degradation on profiles. These two electropherograms correspond to the samples filled to maximum volume and either stored 2 days at +4°C (Figure 5c , RQI = 8.2) or sent immediately (Figure 5d , RQI = 9.1).
The results obtained from the blind test allowed the definition of a suitable sampling procedure in routine conditions despite a limited number of samples analyzed. Consequently, the recommended procedure is to use the PAXgene® tubes as the last tubes drawn in the phlebotomy procedure (after blood collected in other tubes), filled to maximum level. Immediately after collection of blood, the PAXgene® tubes should be gently inverted 8-10 times and stored upright between 18°C to 25°C for a minimum of 1 to 2 h. Then, the samples including urine and blood can be sent to the laboratory by including freeze packs as usual for routine analysis.
Long-term storage condition
To appraise the long-term storage, it was decided to compare two aliquots of the same sample on increasing periods of storage. For this purpose, during samples collection, two PAXgene® blood RNA tubes were filled with blood from the same horse. The first was analyzed at sample reception and the second was stored at À20°C. This study was composed of 62 horse samples and 9 different periods of time storage were selected. Thus, the second PAXgene® tube of each sample was defrosted at either 6 months (n = 12), 8 months (n = 4), 13 months (n = 11), 18 months (n = 3), 19 months (n = 6), 22 months (n = 5), 27 months (n = 6), 28 months (n = 4), or 29 months (n = 11) after analysis of the first tube. After extraction and purification, RNA was quantified on a Nanodrop ND-1000 to compare RNA yield between the first and the second PAXgene® tubes from the same paired sample ( Figure 6 ). Reliable preservation of samples for up to one year at À20°C can be observed. After this period, an increase of RNA yield variation is observed, up to a value close to 45 percent after 2 years. In other Figure 4 . Biological passport sample kit containing 3 bottles which have a blue embossed number, all with a security cap and sealed with a shrinksleeve wrap, two security bags, one plastic bag, two pairs of gloves, sixteen small barcode labels with their unique 7-digit number, one needle, six lithium heparinized tubes for routine screening, one EDTA for haematological parameters and two PAXgene® blood RNA tubes (2.5 mL) for gene expression.
words, a 2-fold decrease is observed in RNA yield after 2 years. Thus, we have established a limit of sample time storage in order to guarantee the integrity of results by having enough material in the case of possible delayed B sample analysis. The proposed stability of human intracellular RNA for 50 months at À20°C was longer than the 12 months observed at À20°C for horses. However, it should be noted that storing the samples at À80°C could improve sample storage conditions [19] and still needs to be assessed.
Conclusion
This study demonstrated the potential application of the use of a dedicated Human IVD PAXgene® Blood RNA Kit combined with the QIACube automated RNA extraction platform and the BioRad RT-qPCR platform for gene expression analysis applied to the horse biological passport. The commercial kit was validated only on human blood samples and required adaptation and optimization of specific technical steps for equine blood samples. In addition, PAXgene® sample collection and storage were also assessed in order to establish the appropriate conditions to obtain RNA material in sufficient quantity and quality. As a result, we recommend that the PAXgene® tubes be carefully filled to maximum capacity (2.5 mL) and that the tubes be stored at low temperature (4°C) during transport or even if possible frozen at À20°C. A 2-fold decrease in RNA yield was demonstrated after about 2 years of storage at À20°C. We thus recommend keeping samples for no more than 1-1.5 years (10-20% variation) because after 18 months of storage, the sample degrades too much to allow enough RNA to be extracted. Nevertheless, an assessment of longterm storage conditions at À80°C could allow this period to be extended. According to the optimized extraction protocol presented in this article, the RNA yield and quality were suitable for downstream gene expression analysis by qPCR techniques considering the recommended quality controls.
